skip to Main Content

All Press Releases

PILA PHARMA publishes year-end report (1 January – 31 December 2022)

Malmö, 28 February 2023 Download the press release as PDF here PILA PHARMA AB (publ) (FN STO: PILA) today publishes the Company´s year-end report for the period January – December 2022. The report can be found on the Company´s website:https://pilapharma.com/investors/finansiell-information/ SUMMARY OF YEAR-END REPORT Fourth quarter (1 October - 31 December 2022) Revenue was 413 kSEK (719) Operating loss (EBIT) was -1…

Read more

PILA PHARMA publicerar bokslutskommuniké (1 januari-31 december 2022)

Malmö, 28 februari 2023 Läs pressmeddelandet som PDF här PILA PHARMA AB (publ) (FN STO: PILA) publicerar i dag bolagets bokslutskommuniké för perioden januari – december 2022 som finns att ta del av på bolagets hemsida: https://pilapharma.com/investors/finansiell-information/ SAMMANFATTNING AV BOKSLUTSKOMMUNIKÉ Fjärde kvartalet (1 oktober - 31 december 2022) Rörelsens intäkter uppgick till 413 kSEK (719) Rörelseresultatet (EBIT) uppgick till -1 951…

Read more

Pila Pharma completes 13-week safety studies in “non-rodents” with no adverse signals during the dosing phase

Malmö, January 30, 2023 Download the press release as PDF here PILA PHARMA AB (publ) (FN STO: PILA) today publishes that a 13-week oral safety study with the development candidate XEN-D0501 in non-rodents has completed the in-life phase with no adverse signals during the dosing phase and biological samples have now been received for assay.  Outstanding investigations still to be completed include…

Read more

Contact us

FÅ PRESSMEDDELANDEN
GET PRESS RELEASES

Back To Top
Search